RU2018124487A - Лечение внутрипеченочного холестаза и родственных заболеваний печени - Google Patents

Лечение внутрипеченочного холестаза и родственных заболеваний печени Download PDF

Info

Publication number
RU2018124487A
RU2018124487A RU2018124487A RU2018124487A RU2018124487A RU 2018124487 A RU2018124487 A RU 2018124487A RU 2018124487 A RU2018124487 A RU 2018124487A RU 2018124487 A RU2018124487 A RU 2018124487A RU 2018124487 A RU2018124487 A RU 2018124487A
Authority
RU
Russia
Prior art keywords
intrahepatic cholestasis
treatment
liver diseases
related liver
subject
Prior art date
Application number
RU2018124487A
Other languages
English (en)
Other versions
RU2743405C2 (ru
RU2018124487A3 (ru
Inventor
Фредрик КАРЛСОН
Бо МЁЛЬСТАМ
Original Assignee
Метабоген Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метабоген Аб filed Critical Метабоген Аб
Publication of RU2018124487A publication Critical patent/RU2018124487A/ru
Publication of RU2018124487A3 publication Critical patent/RU2018124487A3/ru
Application granted granted Critical
Publication of RU2743405C2 publication Critical patent/RU2743405C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Claims (1)

  1. Изобретение относится к способу лечения или снижения опасности внутрипеченочного холестаза у субъекта, нуждающегося в этом, включающему введение субъекту терапевтически эффективного количества композиции, включающей по меньшей мере один бактериальный вид или штамм, включающий активность деконъюгации/гидролиза и/или активность 7-эпимеризации желчных кислот, причем посредством этого лечится или снижается опасность внутрипеченочного холестаза у субъекта, нуждающегося в этом. Также описываются композиции для применения в таких способах.
RU2018124487A 2015-12-14 2016-12-14 Лечение внутрипеченочного холестаза и родственных заболеваний печени RU2743405C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266771P 2015-12-14 2015-12-14
US62/266,771 2015-12-14
PCT/EP2016/080941 WO2017102816A1 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Publications (3)

Publication Number Publication Date
RU2018124487A true RU2018124487A (ru) 2020-01-10
RU2018124487A3 RU2018124487A3 (ru) 2020-05-29
RU2743405C2 RU2743405C2 (ru) 2021-02-18

Family

ID=57570064

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018124487A RU2743405C2 (ru) 2015-12-14 2016-12-14 Лечение внутрипеченочного холестаза и родственных заболеваний печени

Country Status (16)

Country Link
US (1) US20180369297A1 (ru)
EP (1) EP3389680B1 (ru)
JP (2) JP2018537484A (ru)
KR (1) KR20180094950A (ru)
CN (1) CN109069548A (ru)
AU (1) AU2016374365B2 (ru)
BR (1) BR112018012022A2 (ru)
CA (1) CA3008195A1 (ru)
CL (1) CL2018001548A1 (ru)
ES (1) ES2962302T3 (ru)
IL (1) IL259480B2 (ru)
MX (1) MX2018007227A (ru)
RU (1) RU2743405C2 (ru)
SG (1) SG11201804255QA (ru)
WO (1) WO2017102816A1 (ru)
ZA (1) ZA201804660B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
CN111212655A (zh) * 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN112280720B (zh) * 2020-11-19 2021-07-13 山东龙昌动物保健品有限公司 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
CA2374937A1 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
MY148872A (en) * 2006-02-15 2013-06-14 Nestec Sa Use of bifidobacterium longum for the prevention and treatment of inflammation
US20120128633A1 (en) * 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒
WO2015051323A1 (en) * 2013-10-03 2015-04-09 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof

Also Published As

Publication number Publication date
KR20180094950A (ko) 2018-08-24
AU2016374365B2 (en) 2023-04-13
CL2018001548A1 (es) 2018-07-20
IL259480A (en) 2018-07-31
EP3389680B1 (en) 2023-10-11
BR112018012022A2 (pt) 2018-12-04
MX2018007227A (es) 2018-08-01
IL259480B1 (en) 2023-05-01
SG11201804255QA (en) 2018-06-28
WO2017102816A1 (en) 2017-06-22
RU2743405C2 (ru) 2021-02-18
EP3389680A1 (en) 2018-10-24
JP2022166039A (ja) 2022-11-01
AU2016374365A1 (en) 2018-07-12
US20180369297A1 (en) 2018-12-27
EP3389680C0 (en) 2023-10-11
CN109069548A (zh) 2018-12-21
ES2962302T3 (es) 2024-03-18
CA3008195A1 (en) 2017-06-22
ZA201804660B (en) 2022-12-21
RU2018124487A3 (ru) 2020-05-29
JP2018537484A (ja) 2018-12-20
IL259480B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
RU2018124487A (ru) Лечение внутрипеченочного холестаза и родственных заболеваний печени
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
MX2018004043A (es) Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2020012034A (es) Inhibidores de furina.
MX2017000612A (es) Inhibidores de tirosina quinasa del bazo (syk).
EP3533877A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
EA201791518A1 (ru) Способы лечения заболеваний сетчатки
EA201791993A1 (ru) Способы лечения протеинопатий
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
WO2014151456A3 (en) Treatment of inflammatory diseases
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
EA201890878A1 (ru) Способ лечения медуллобластомы с помощью ингибитора ezh2
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
WO2016004404A3 (en) Gls1 inhibitors for treating disease
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
ZA202002103B (en) Compounds as mpges-1 inhibitors